We envision a world where we feel tomorrow is another day.
News
- Initiated Phase 1/ 2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory acute myeloid leukemia or myelodysplastic syndrome in the U.S.
- Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor according to License Agreement with Ono Pharmaceutical
- Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.
Science
Company
- Corporate Name
- Chordia Therapeutics Inc.
- Foundation
- November 1, 2017
- Head Office
- 26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-0012 Japan
- Tokyo Office
- 3-11-5,Nihonbashi-honcho,
Chuo-ku,Tokyo 103-0023 Japan
- Representative
- Hiroshi Miyake, Ph.D. CEO
